- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03309449
A Usability Assessment of Naloxone by Community Members
A Usability Assessment of Intramuscular, Atomized Intranasal, and Nasal Spray Administration of Naloxone by Community Members
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objectives:
- Primary: The successful administration of simulated naloxone. A successful administration will be defined as administration of the simulated naloxone to the mannequin head or simulated flesh pad within 10 minutes and without any critical errors (defined below).
- Secondary: Total time required to successfully administer the simulated naloxone.
Design: Single site, open-label, randomized usability assessment of intramuscular, intranasal, and nasal spray administration of simulated naloxone. A convenience sample of participants will consent to volunteer in the study at a public venue. Participants will provide verbal consent and will be randomly assigned a simulated naloxone kit containing either intramuscular, intranasal, or nasal spray administration materials. Participants will be shown an instructional video demonstrating how to appropriately assemble and administer the simulated naloxone kit they were randomly assigned. Once the video is complete the individual will enter a use scenario station where they will be asked to assemble and administer the simulated naloxone kit to a mannequin (intranasal and nasal spray) or simulated flesh pad (intramuscular). The participant will be instructed to start and will be timed until the simulated naloxone has been successfully administered or 10 minutes has elapsed. The participant will be observed by one trained investigator who will assess for successful administration of the simulated naloxone and critical errors. The environment will contain distractors (radio playing) and items that will simulate a community based dwelling (table, chairs, and an inflatable mattress). The mannequin and simulated flesh pad will be located on the mattress. Once the participant has successfully administered simulated naloxone or 10 minutes elapses the timer will be stopped. Successful administration of simulated naloxone will be defined as administration of the agent without any critical errors occurring (defined below). Data collected will include demographics (defined below), successful administration of simulated naloxone, and time to successful administration of simulated naloxone.
Statistical Methods: All data will be analyzed using IBM SPSS Statistics software. Demographics data will be analyzed using descriptive statistics for continuous measures and percentages for categorical measures. The successful administration of naloxone will be compared between groups using the Chi-square test and a significant difference will be defined as a p-value of less than 0.05 for the result. The time to administration between groups will be assessed using a one-way ANOVA and a significant difference will be defined as a p-value of less than 0.05 for the result.
Data Analysis/Interpretation: As stated above data will be collected to assess both the successful administration of and time to administration of naloxone. The rate of successful administration will be reported as a percentage for each of the three groups and analyzed using the Chi-square test. Successful administration is defined as administration of the simulated naloxone within 10 minutes without committing any critical errors. Critical errors are as follows:
- Intranasal (atomizer): failure to remove both yellow caps from bristoject, failure to remove cap from simulated naloxone, failure to attach atomizer, failure to attach simulated naloxone, drug leak prior to administration, administration in only one nostril, and failure to administer within 10 minutes.
- Intramuscular: failure to attach the needle to the syringe, failure to remove cap from simulated naloxone, failure to draw up >90% (0.9 mL) of the simulated naloxone, failure to puncture simulated flesh pad with needle, failure to push entire volume of fluid in the syringe into the simulated flesh pad, and failure to administer within 10 minutes.
- Intranasal (spray): failure to place the tip of the device into one nostril, failure to depress the device and release the simulated naloxone, failure to administer within 10 minutes.
Time to successful administration will be reported using descriptive statistics (mean time to administration) and analyzed using a one-way ANOVA. Times for participants who commit a critical error or who do no administer the simulated naloxone within 10 minutes will not be included in the analysis.
A route of administration will be considered to be more user-friendly if it demonstrates a statistically significantly higher rate of successful administration compared to another route of administration.
Study Procedures: No study procedures will be performed on study participants.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- healthy adults at least 18 years of age
Exclusion Criteria:
- severely visually or hearing impaired (defined as: legally deaf, legally blind, unable to read print size provided on instructional handout, or unable to hear video audio), previous naloxone administration training, not English proficient, previously participated in the trial, or pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Intramuscular administration
Participants in this arm will be provided with the training and supplies to administer intramuscular simulated naloxone using a syringe and needle to a simulated flesh pad on a mannequin.
|
Intramuscular administration of simulated naloxone
|
Other: Intranasal (Atomizer)
Participants in this arm will be provided with the training and supplies to administer atomized intranasal simulated naloxone to a mannequin via a syringe using an intranasal mucosal atomization device.
|
Intranasal atomizer administration of simulated naloxone
|
Other: Intranasal (Spray)
Participants in this arm will be provided with the training and supplies to administer an intranasal spray simulated naloxone to a mannequin.
|
Nasal spray administration of simulated naloxone
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Successful Administration of Naloxone
Time Frame: 10 minutes
|
A successful administration will be defined as administration of the simulated naloxone to the mannequin head or simulated flesh pad within 10 minutes and without any critical errors.
Critical errors include: Failure to attach the needle to the syringe, failure to place the device tip into a nostril, failure to remove both caps from the device, failure to remove the cap from the naloxone, failure to depress the device and release the naloxone into the nostril, failure to remove cap from the naloxone, failure to draw up > 90% (0.9 ml) of the naloxone, failure to attach atomizer to the device, failure to puncture the simulated flesh pad with the needle, failure to attach the naloxone to the device, failure to push the naloxone into the simulated flesh pad, drug leakage before administration, and administration of the total volume in a single nostril.
|
10 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Successful Administration of Naloxone
Time Frame: 10 minutes
|
The time required to successfully administer the simulated naloxone will be reported for each group.
Only participants who were successful administering naloxone were included in this analysis.
|
10 minutes
|
Collaborators and Investigators
Investigators
- Principal Investigator: William Eggleston, PharmD, State University of New York - Upstate Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 922070-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Overdose
-
NHS Greater Glasgow and ClydePublic Health ScotlandRecruitingDrug Effect | Drug Use | Drug Abuse | Drug Toxicity | Illicit Drug Use | Overdose, Drug | Illicit Drug Overdose | Illicit Drug IntoxicationUnited Kingdom
-
Oregon Health and Science UniversityOregon State University; Oregon Department of Corrections; CODA Inc.; Bridgeway... and other collaboratorsCompleted
-
Emergent BioSolutionsCompletedOpioid OverdoseUnited States
-
University Hospital Bispebjerg and FrederiksbergCompletedDrug Overdose | Overdose of Beta-adrenergic Blocking DrugDenmark
-
San Francisco Department of Public HealthCompletedOpioid-Related Disorders | Drug OverdoseUnited States
-
San Francisco Department of Public HealthRecruitingStimulant Overdose | Overdose Accidental | Overdose Cocaine | Overdose MethamphetamineUnited States
-
University of CincinnatiNational Institute on Drug Abuse (NIDA)CompletedOpioid-Related Disorders | Substance Abuse | Drug Overdose | Drug Abuse | Drug AddictionUnited States
-
Mikkel Bring ChristensenCompletedBlood Pressure | Drug Overdose | Overdose of Beta-adrenergic Blocking DrugDenmark
-
Nationwide Children's HospitalRecruitingHarm Reduction | Opiate Overdose | Fentanyl OverdoseUnited States
-
Nationwide Children's HospitalRecruitingHarm Reduction | Opiate Overdose | Fentanyl OverdoseUnited States
Clinical Trials on Syringe and needle
-
ShireCompletedShort Bowel SyndromeUnited States, Canada, Finland, Italy, United Kingdom, Belgium
-
Microdermics Inc.CompletedIntradermal InjectionCanada
-
Serum Institute of India Pvt. Ltd.PATHTerminatedImmune Response to DTP-HB-Hib VaccineIndia
-
PATHWorld Health Organization; University of Cape TownCompleted
-
The University of Texas Health Science Center,...WithdrawnPain | Epidural AnalgesiaUnited States
-
Neurophth Therapeutics IncRecruitingLeber Hereditary Optic Neuropathy (LHON)United States
-
Cairo UniversityUnknown
-
Universidade do PortoCompleted
-
Medical Research Council Unit, The GambiaCenters for Disease Control and Prevention; World Health OrganizationCompleted
-
Sheba Medical CenterUnknown